Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Published . Updated .
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BMY BRISTOL-MYERS SQUIBB CO
GA selected BMY as a RELATED security because its canonical security name directly matches this event's themes: bristol, myers. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Source: BioPharma Dive
The price since 18 Sep 2026: Acadia Healthcare (ACHC) versus the S&P 500
Since the first closing price after “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” Acadia Healthcare (ACHC) is +6.45%. The S&P 500 fund (SPY) is -0.89% over the same days, a +7.35% difference versus the market.
Who reported a Acadia Healthcare (ACHC) trade near this story
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies carried with this story
- ACHC Acadia Healthcare
For “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BMY Bristol Myers Squibb
In “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” Bristol Myers Squibb (BMY) is linked, with no stored direction, medium confidence. Reason on file: GA selected BMY as a RELATED security because its canonical security name directly matches this event's themes: bristol, myers. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- CRDF Cardiff Oncology
For “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
The 18 Sep 2026 story “Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug” names Acadia Healthcare (ACHC) because of this story.
What ties Acadia Healthcare (ACHC) to the headline is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
What the saved facts support for Acadia Healthcare (ACHC)
46 out of 100
“Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.